NCT02343952 - Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2015

Primary Completion Date

August 10, 2020

Study Completion Date

January 1, 2021

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Pembrolizumab

Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.

Trial Locations (15)

University of Virginia Health System, Charlottesville

University of Louisville, James Graham Brown Cancer Center, Louisville

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

IU Health Central Indiana Cancer Centers, Indianapolis

IU Health Goshen Hospital, Goshen

Northern Indiana Cancer Research Consortium, South Bend

Fort Wayne Oncology & Hematology, Inc., Fort Wayne

IU Health at Ball Memorial Hospital, Muncie

Oncology Hematology Associates of SW Indiana, Newburgh

IU Health Arnett Cancer Center, Lafayette

Horizon Oncology Research, Inc., Lafayette

Community Regional Cancer Care, Indianapolis

Nebraska Cancer Specialists, Omaha

City of Hope Comprehensive Cancer Center, Duarte

Rutgers Cancer Institute of New Jersey, New Brunswick